Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome

Seminars in Liver Disease

Volumn 20, Issue 1, 2000, Pages 17-35

  Alter, Harvey J ^a,b   Seeff, Leonard B ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Chronic hepatitis; Cirrhosis; Fibrosis; HCV

Indexed keywords

ARTICLE; DISEASE COURSE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS;

ACUTE DISEASE; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; UNITED STATES; WORLD HEALTH ORGANIZATION;

EID: 0033932001     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Dienstag JL. Non-A, non-B hepatitis. I. Recognition, epidemiology and clinical features. Gastroenterology 1983;85:439-462
2. Seeff LB. Hepatitis C from a needlestick injury. Ann Intern Med 1991;115:411
3. Alter HJ, Purcell RH, Holland PV, Popper H. Transmissible agent in non-A, non-B hepatitis. Lancet 1978;1:459-463
4. Tabor E, Gerety RJ, Drucker JA, et al. Transmission of non-A, non-B hepatitis from man to chimpanzee. Lancet 1978;1: 463-466
5. Tabor E, Purcell RH, Gerety RJ. Primate animal models and titered inocula for the study of human hepatitis A, B, and non-A, non-B hepatitis. J Med Primatol 1981;1:305-318
6. Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of cDNA clone derived from blood-borne non-A, non-B viral hepatitis genome. Science 1989;244: 359-362
7. Alter HJ. Chronic consequences of non-A, non-B hepatitis. In: Seeff LB, Lewis JH, eds. Hepatology: Festschrift for Hyman J. Zimmerman, M.D. New York: Plenum Press, 1989, pp. 83-97
8. Gilliam JH III, Geisinger KR, Richter JE. Primary hepatocellular carcinoma after chronic non-A, non-B post-transfusion hepatitis. Ann Intern Med 1984;101:794-794
9. Kiyosawa K, Sodeyama T, Tanaka E, et al. interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-675
10. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332: 1463-1466
11. Bruix J Barrera JM, Calvet X, et al. Prevalence of antibody to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989;2:1004-1006
12. Colombo M, Kuo G, Choo QL, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989;2:1006-1008
13. Alter HJ, Conry-Cantilena C, Melpolder J, Tan D, Van Raden M, Herion D, Lau D, Hoofnagle JH. Hepatitis C in asymptomatic blood donors. Hepatology 1997;26(Suppl 1):29S-33S
14. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-1905
15. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-562
16. Pessoa MG, Wright TL. Hepatitis C infection in transplantation. Clin Liver Dis 1997;1:663-690
17. Farci P, Alter HJ, Govindarajan S, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992;258:135-140
18. Shimizu YK, Yoshikuta H, Hijikata M, Iwamoto A, Alter HJ, Purcell RH. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutants. J Virol 1994;68:1494-1500
19. Rosa D, Campagnoli S, Moretto C, et al. A quantitative test to estimate neutralizing antibodies to the hepatitis c virus: Cytofluorometric assessment of envelop glycoprotein 2 binding to target cells. Proc Natl Acad Sci USA 1996 93;1759-1763
20. Farci P, Shimoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Proc Natl Acad Sci USA (in press)
21. Bukh J, Yanagi M, Emerson SU, Purcell RH. Course of infection and evolution of monoclonal hepatitis C virus (HCV) strain H77 in chimpanzees transfected with RNA transcripts from an infectious cDNA clone. Hepatology 1998;28:319A.
22. Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence. Hepatology 1999;30:595-601.
23. Lai ME, Mazzoleni AP, Argiolu F, De Virgilis S, Balastrieri A, Purcell RH, Farci P. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994;343:388-390
24. Weiner A, Erickson AL, Kansopon J, et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci USA 1995;92:2755-2759
25. Eyster ME, Diamondstone LS, Lien JM. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Def Syndr 1993;6:602-610
26. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-1340
27. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study. Hepatology 1998;28:1687-1695
28. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14:969-974
29. Koretz RL, Abbey H, Cloeman E, Gitnick G. Non-A, non-B post-transfusion hepatitis: Looking back in the second decade. Ann Intern Med 1993;119:110-115
30. Mattson L, Sonnerborg A, Weiland O. Outcome of acute asymptomatic non-A, non-B hepatitis: A 13-year follow-up study of hepatitis C virus markers. Liver 1993;13:274-278
31. Tremolada F, Casarin C, Albert A, Drago C, Tagger A, Ribero ML, Realdi G. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992;16:273-281
32. Alter HJ, Purcell RH, Feinstone SM, Holland PV, Morrow AG. Non-A/non-B hepatitis: A review and interim report of an ongoing prospective study. In: Vyas GN, Cohen SN, Schmid R, eds. Viral Hepatitis: A Contemporary Assessment of Etiology, Epidemiology, Pathogenesis and Prevention. Philadelphia: Franklin Institute Press, 1978, pp. 359-369
33. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327:1906-1911
34. Seeff LB, Zimmerman HJ, Wright EC, et al. A randomized, double-blind, controlled trial of the efficacy of immune serum globulin in the prevention of post-transfusion hepatitis: A Veterans Administration cooperative study. Gastroenterology 1977;72: 111-121
35. Seeff LB, Wright EC, Zimmerman HJ, et al. Posttransfusion hepatitis, 1973-1975: A Veterans Administration cooperative study. In: Vyas GN, Cohen SN, Schmid R, eds. Viral Hepatitis: A Contemporary Assessment of Etiology, Epidemiology, Pathogenesis and Prevention. Philadelphia: Franklin Institute Press, 1978, pp. 371-381
36. Aach RD, Szmuness W, Mosley JW, et al. Serum alanine aminotransferase of donors in relation to risk of non-A, non-B hepatitis in recipients: The Transfusion-Transmitted Viruses Study. N Engl J Med 1981;304:989-994
37. Knodell RG, Conrad ME, Ginsberg AL, Bell CJ, Flanery EP. Efficacy of prophylactic gamma-globulin in preventing non-A, non-B hepatitis. Lancet 1976;1:557-561
38. Wright EC, Seeff LB, Hollinger FB, Alter HJ, Buskell-Bales Z, Cain C, the NHLBI Study Group. Updated long-term mortality of transfusion- associated hepatitis (TAH), non-A, non-B and C. Hepatology 1998;28:272A
39. Seeff LB, Hollinger FB, Alter HJ, Wright EC, Bales ZB, the NHLBI Study Group. Long-term morbidity of transfusion-associated hepatitis (TAH) C. Hepatology 1998;28:407A
40. Denny FW, Wannamaker LW, Brink WR, Rammelkamp H. Prevention of rheumatic fever, treatment of preceding streptococcic infection. JAMA 1950;143:151-153
41. Seeff LB, Miller RN, Rabkin CS, Bales ZB, Smoak BL, Johnson LD, Kaplan EL. 45-Year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132:105-111
42. Conry-Cantilena, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334: 1691-1696
43. Shakil AO, Conry-Cantilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: Clinical, biochemical, virologic and histologic features. Ann Intern Med 1995;123: 330-337
44. Kenny-Walsh E for the Irish Hepatology Research Group. Clinical outcomes after hepatitis infection from contaminated antiglobulin. N Engl J Med 1999;340:1228-1233
45. Muller R. The natural history of hepatitis C: Clinical experiences. J Hepatol 1996;24(Suppl):52-54
46. Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999;341:866-870
47. Locasciulli A, Testa M, Pontisso P, et al. Prevalence and natural history of hepatitis C infection in patients cured of childhood leukemia. Blood 1997;11:4628-4633
48. Garcia-Monzon C, Jara P, Fernandez-Bermejo M, et al. Chronic hepatitis C in children: A clinical and immunohistochemical comparative study with adults. Hepatology 1998;28: 1696-1701
49. Luban N, Post J, Glymph C. Transfusion associated hepatitis C and G in pediatric patients identified through a universal lookback approach. Transfusion 1999;106(Suppl):110S
50. Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitisC. Lancet 1997;349:825-832
51. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472
52. Serfaty L, Aumaitre H, Chazouilleres O, Bonand A-M, Rosmorduc O, Poupon RE, Poupon R. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27:1435-1440
53. Nishioka K, Watanabe J, Furuta S, et al. A high prevalence of the antibody to hepatitis C virus with hepatocellular carcinoma in Japan. Cancer 1991;67:429-433
54. Kato Y, Nakata K, Omagari K, et al. Risk of hepatocellular carcinoma in patients with cirrhosis in Japan: Analysis of infectious hepatitis viruses. Cancer 1994;74:2234-2238
55. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National Surveillance Program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Int Med 1999;131:174-181
56. Chen P-J, Chen D-S. Hepatitis B virus and hepatocellular carcinoma. In: Okuda K, Tabor E, eds. Liver Cancer. New York: Churchill Livingstone, 1997, pp. 29-37
57. Hadziyannis S, Tabor E, Kaklamani E, et al. A case-control study of hepatitis B and C virus infections in the etiology of hepatocellular carcinoma. Int J Cancer 1995;60:627-631
58. Kew MC, Houghton M, Choo QL, Kuo G. Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma. Lancet 1990;335:873-874
59. Yu MC, Tong MJ, Coursaget P, et al. Prevalence of hepatitis B and C markers in black and white patients with hepatocellular carcinoma in the United States. J Natl Cancer Inst 1990;82: 1038-1041
60. Di Bisceglie AM, Order SE, Klein JL, et al. The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. Am J Gastroenterol 1991;86:335-338
61. Hassan F, Jeffers LJ, Medina M, et al. Hepatitis C-associated hepatocellular carcinoma. Hepatology 1990;12:589-591
62. Liang TJ, Jeffers LJ, Reddy KR, et al. Viral pathogenesis of hepatocellular carcinoma on the United States. Hepatology 1993; 18:1326-1333
63. Gordon SC, Eloway RS, Long JC, et al. The pathology of hepatitis C as a function of mode of transmission. Blood transfusion versus intravenous drug use. Hepatology 1993;18:1338-1343
64. Pozatto G, Kaneko S, Moretti, M, et al. Different genotypes of hepatitis C virus are associated witrh different severity of chronic liver disease. J Med 1994;43:291
65. Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997;26(Suppl 1):122S
66. Gretch D, Corey L, Wilson J, et al. Assessment of hepatitis C virus RNA levels by competetive RNA polymerase chain reaction: High titer viremia correlates with advanced stage of disease. J Infect Dis 1994;169:1219-1225
67. Bjorkander J, Cunningham-Runnels C, Lundin P, Olsson R, Soderstrom R, Hanson LA. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. Am J Med 1988;84:107-111
68. Bjoro K, Froland SS, Yun Z, et al. Hepatitis C infection inpatients with primary hypogammmaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994;331: 1607-1611
69. Tefler P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C. The progression of HCV-associated liver disease in a cohort of hemophilic patients. Br J Haemotol 1994;87:555-561
70. Markis M, Preston FE, Rosendaal FR, Underwood JCE, Rice KM, Triger DR. The natural history of chronic hepatits C in hemophiliacs. Br J Haemotol 1996;94:746-752
71. Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in hemophiliac men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997;350:1425-1431
72. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999;29:908-914
73. Thursz M, Rhiannon Y, Goldin R, Trepo C, Thomas HC. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. Lancet 1999;354:2119-2124
74. Aikawa T, Kojima M, Onishi H, et al. HLA DRB1 and DQB1 alleles and haplotypes influencing the progression of hepatitis C. J Med Virol 1996;49:274-278
75. Bellentani SW, Pozzato G, Saccoccio G, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: Report from the Dionysos study. Gut 1999;44:874-880
76. Corrao G, Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 1998;27:914-919
77. Ostapowicz G, Watson KSR, Locarnini A, Desmond P. Role of alcohol in the prognosis of liver disease caused by hepatitis C virus infection. Hepatology 1998;27:1730-1735
78. Gomez MR, Nogales MC, Grande L, et al. Alcohol consumption enhances intrahepatic hepatitis C virus replication. Hepatology 1998;28:280A
79. Wiley TE, McCarthy M, Breide L, McCarthy M, Layden T. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998;28:805-809
80. McHutchison JG, Gorden SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492